B cell deficiency promotes the initiation and progression of lung cancer

Currently commercialized CAR-T cell therapies targeting CD19 and BCMA show great efficacy to cure B cell malignancies. However, intravenous infusion of these CAR-T cells severely destroys both transformed and normal B cells in most tissues and organs, in particular lung, leading to a critical questi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Han, Chen, Chen, Gu, Lixing, Li, Jiapeng, Yue, Yunqiang, Lyu, Mengqing, Cui, Yeting, Zhang, Xiaoyu, Liu, Yu, Zhu, Haichuan, Liao, Xinghua, Zhang, Tongcun, Sun, Fan, Hu, Weidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556970/
https://www.ncbi.nlm.nih.gov/pubmed/36249034
http://dx.doi.org/10.3389/fonc.2022.1006477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556970/
https://www.ncbi.nlm.nih.gov/pubmed/36249034
http://dx.doi.org/10.3389/fonc.2022.1006477

Ejemplares similares